NewsRoom Articles - Page 35 of 115 - CanadianCannabisWire

MondayAug 09, 2021 1:48 pm

Flora Growth Corp. (NASDAQ: FLGC) Receives Fair Value Estimate, Coverage from Argus Research Company; Developing Growth Opportunities by Columbia’s Cannabis Law, Headquarter Relocation

Flora Growth Corp recently received coverage from Argus Research, which gives the company’s stock a fair value estimate of $7.50 against the $3.24 recorded July 20 Argus also projects that Flora’s revenue would increase to $9 million in 2021 and $31 million in 2022, up from $0.1 million reported in 2020 Flora received a boost in its operations when Colombia’s president accepted and signed reforms to the existing cannabis legislation The updated law allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible and medical products and removes marketing limitations on cannabis products in Colombia Flora is also…

MondayAug 09, 2021 1:04 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise

InMed announced a non-binding letter of intent to acquire BayMedica Inc. The move is designed to grow InMed’s market presence and strengthen its operations The two companies have had a reciprocal research collaboration that dates back to November 2020 InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028 InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various…

FridayAug 06, 2021 9:30 am

First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls

Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls The complete results of the study will be produced as sample and data analyses work are completed Lexaria is…

FridayAug 06, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine Cannabis in sports medicine took center stage at the Tokyo Olympics American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group's dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps…

WednesdayAug 04, 2021 11:10 am

RYAH Group Inc. (CSE: RYAH) Supporting U.S. Changes in Cannabis Research

New cultivators have approved for federally funded studies in the U.S., and 575 DEA-licensed researchers are standing by, ready for the change RYAH's ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research RYAH continues to expand its global clinical and distribution network for plant-based medicine and digital patient care The U.S. is putting an end to its 50-year long prohibition on Cannabis Research (https://cnw.fm/UOoHf). New cultivators have now been approved for federally funded studies. With over 575 DEA-licensed researchers across the U.S., the future of cannabis…

TuesdayAug 03, 2021 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’

InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…

TuesdayAug 03, 2021 9:00 am

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Names New Executive, Retains PR Firm

CHALF appoints retail veteran Ginger Mollo as chief integration officer, Fifth & Root GM Mollo will oversee the positioning, expansion of the Fifth & Root Brand within the health and wellness beauty market as well as integration into Chalice brands Chalice has engaged MP-IMC to heighten profile of Fifth & Root in Chalice Brands product portfolio Chalice Brands (CSE: CHAL) (OTCQB: CHALF), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, has appointed retail veteran Ginger Mollo as chief integration officer for the company. In addition, Mollo will also serve as general manager of Fifth &…

MondayAug 02, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives

Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as…

FridayJul 30, 2021 9:00 am

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Reports Record Q2 2021 Revenues

Company executed record quarter by focusing on profitable operations, accretive acquisition of Homegrown Oregon Chalice posts record quarterly revenue, gross profit numbers Homegrown chain of five stores joined the Chalice brand earlier this year Chalice Brands (CSE: CHAL) (OTCQB: CHALF) has released its 2021 second-quarter unaudited financial, noting highest-ever quarterly revenues, along with other promising numbers (https://cnw.fm/N4NXU). The company is a premier consumer-driven company specializing in the retail, production, processing, wholesale and distribution of cannabis. “We are immensely proud to execute another record quarter by focusing on profitable operations and the accretive acquisition of Homegrown Oregon,” stated Chalice CEO and…

ThursdayJul 29, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability

Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses The company envisions building on its recent successes with larger studies of the…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000